@article{Liu_X-2021_42328,
title = {Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial},
author = {Liu, X. and Shaw, R. and Stuart, A. and Greenland, M. and Aley, P. and Andrews, N. and Cameron, C. and Charlton, S. and Clutterbuck, E. and Collins, A. and Dinesh, T. and England, A. and Faust, S. and Ferreira, D. and Finn, A. and Green, C. and Hallis, B. and Heath, P. and Hill, H. and Lambe, T. and Lazarus, R. and Libri, V. and Long, F. and Mujadidi, Y. and Plested, E. and Provstgaard-Morys, S. and Ramasamy, M. and Ramsay, M. and Read, R. and Robinson, H. and Singh, N. and Turner, D. and Turner, P. and Walker, L. and White, R. and Nguyen-Van-Tam, J. and Snape, M. and Com-COV Study Group},
month = {aug},
year = {2021},
abstract = {Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer–BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.},
pages = {856-869},
volume = {398},
issue = {10303},
journal = {The Lancet},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S0140-6736(21)01694-9},
}
